FR2859910B1 - Utilisation du 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27- bishomo-20-epi-cholecalciferol pour le traitement de l'hyperplasie benigne de la prostate - Google Patents

Utilisation du 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27- bishomo-20-epi-cholecalciferol pour le traitement de l'hyperplasie benigne de la prostate

Info

Publication number
FR2859910B1
FR2859910B1 FR0410073A FR0410073A FR2859910B1 FR 2859910 B1 FR2859910 B1 FR 2859910B1 FR 0410073 A FR0410073 A FR 0410073A FR 0410073 A FR0410073 A FR 0410073A FR 2859910 B1 FR2859910 B1 FR 2859910B1
Authority
FR
France
Prior art keywords
bishomo
cholecalciferol
epi
diene
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0410073A
Other languages
English (en)
French (fr)
Other versions
FR2859910A1 (fr
Inventor
Luciano Adorini
Enrico Colli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxell SpA
Original Assignee
Bioxell SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Bioxell SpA filed Critical Bioxell SpA
Publication of FR2859910A1 publication Critical patent/FR2859910A1/fr
Application granted granted Critical
Publication of FR2859910B1 publication Critical patent/FR2859910B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR0410073A 2003-09-24 2004-09-23 Utilisation du 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27- bishomo-20-epi-cholecalciferol pour le traitement de l'hyperplasie benigne de la prostate Expired - Fee Related FR2859910B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (2)

Publication Number Publication Date
FR2859910A1 FR2859910A1 (fr) 2005-03-25
FR2859910B1 true FR2859910B1 (fr) 2006-04-28

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0410073A Expired - Fee Related FR2859910B1 (fr) 2003-09-24 2004-09-23 Utilisation du 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27- bishomo-20-epi-cholecalciferol pour le traitement de l'hyperplasie benigne de la prostate

Country Status (12)

Country Link
EP (1) EP1673096A1 (zh)
JP (2) JP2007506699A (zh)
CN (1) CN100488511C (zh)
BE (1) BE1016292A3 (zh)
BR (1) BRPI0404050A (zh)
CH (1) CH698144B1 (zh)
EA (1) EA010240B1 (zh)
FR (1) FR2859910B1 (zh)
HK (1) HK1085373A1 (zh)
NL (1) NL1027109C2 (zh)
NZ (1) NZ535531A (zh)
WO (1) WO2005027923A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101027052A (zh) * 2004-10-05 2007-08-29 橘生药品工业株式会社 用于伴下尿路梗阻的集尿障碍的预防和/或治疗剂
ES2378240T3 (es) * 2004-10-06 2012-04-10 Kissei Pharmaceutical Co., Ltd. Composición medicinal para evitar la transición al tratamiento operatorio de la hipertrofia prostática
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906A1 (fr) * 2017-03-20 2018-09-21 Pierre Fabre Medicament Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6100294A (en) * 1997-05-16 2000-08-08 Women And Infants Hospital Cyclic ether vitamin D3 compounds, 1α(OH) 3-epi-vitamin D3 compounds and uses thereof
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
US20030191093A1 (en) * 2001-12-03 2003-10-09 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds

Also Published As

Publication number Publication date
JP2009035559A (ja) 2009-02-19
EP1673096A1 (en) 2006-06-28
NL1027109C2 (nl) 2005-05-03
JP2007506699A (ja) 2007-03-22
HK1085373A1 (en) 2006-08-25
NZ535531A (en) 2006-03-31
EA200401100A1 (ru) 2005-04-28
BE1016292A3 (nl) 2006-07-04
CN100488511C (zh) 2009-05-20
BRPI0404050A (pt) 2005-06-14
NL1027109A1 (nl) 2005-03-29
EA010240B1 (ru) 2008-06-30
CN1615891A (zh) 2005-05-18
FR2859910A1 (fr) 2005-03-25
CH698144B1 (fr) 2009-05-29
WO2005027923A1 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
MA26207A1 (fr) Compositions de traitement de l'eau.
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
DK1294644T3 (da) Vandbehandlingssammensætninger
NO20034877D0 (no) Anvendelse av bifosfonater ved behandling av benmetastase forbundet med prostatakreft
DK1112106T3 (da) Serotonerge 5HT2-agonister til behandling af glaukom
NO20034166L (no) Molekyl¶re konjugater for anvendelse ved behandling av cancer
NO20026008D0 (no) Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
MA25847A1 (fr) Composition pour le traitement du dysfonctionnement endothelial.
DK1764111T3 (da) Vaginalt indgivne anti-dysrytmi midler til behandling af uterin dysrytmi
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
NO20034473L (no) Anvendelse av selektive cox-2-inhibitorer ved behandling av urininkontinens
NO991619D0 (no) Anvendelse av en H+, K+-ATPase-inhibitor i behandlingen av nesepolypper
FR2859910B1 (fr) Utilisation du 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27- bishomo-20-epi-cholecalciferol pour le traitement de l'hyperplasie benigne de la prostate
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
MA27202A1 (fr) Composition pour le traitement de tissus comprenant un agent permettant d'ameliorer l'aspect de la solution de rincage
NO20030978L (no) Behandling av urindysfunksjon
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
ATE250580T1 (de) Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
EP1372639A4 (en) TREATMENT AGENT FOR BLADDER IRRITATION SYMPTOMS ACCOMPANIED WITH BENIGN PROSTATIC HYPERPLASIA
ATE391507T1 (de) S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20110531